Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.51 |
| ▸ | CA1 | P00915 | 6/20 | 0.51 |
| ▸ | CA2 | P00918 | 6/20 | 0.51 |
| ▸ | CA9 | Q16790 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27704055 | 0.90 | TDP1 (0.56) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL754844 | 0.83 | KMT2A (0.56) | KMT2AMAPTTDP1MAPK1MEN1 | |
| SCHEMBL20490967 | 0.83 | NPC1 (0.55) | CA12CA2CA9KMT2AMEN1 | |
| SCHEMBL4126030 | 0.82 | CA12 (0.51) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL27647313 | 0.81 | ALDH1A1 (0.55) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL13670592 | 0.80 | HDAC1 (0.57) | MAPTTDP1L3MBTL1LMNAKDM4E | |
| Thiosemicarbazide SCHEMBL27703889 | 0.80 | POLB (0.46) | CA12CA1CA2CA9MAPT | |
| SCHEMBL4118643 | 0.79 | CA12 (0.52) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL993752 | 0.77 | MAPT (0.58) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL4126847 | 0.77 | ALDH1A1 (0.54) | CA12CA1CA2CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318782-B2 | Mitotic kinesin inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| EP-1847534-B9 | Thiadiazoline derivatives for treating cancer | KYOWA HAKKO KIRIN CO LTD (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20110275827-A1 | Mitotic Kinesin Inhibitor | FUJIFILM CORPORATION (JP) | 2011-11-10 | — | — | US | disclosed |
| EP-1454903-B9 | Thiadiazoline derivatives for treating cancer | KYOWA HAKKO KIRIN CO LTD (JP) | 2011-10-05 | — | — | EP | disclosed |
| EP-1847534-B1 | Thiadiazoline derivatives for treating cancer | KYOWA HAKKO KIRIN CO LTD (JP) | 2011-06-22 | — | — | EP | disclosed |
| EP-2327702-A1 | Mitotic kinesin inhibitor | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-7910611-B2 | Therapeutic agent for restenosis | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7902234-B2 | Thiadiazoline derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20110004000-A1 | Mitotic Kinesin Inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-01-06 | — | — | US | disclosed |
| US-7851635-B2 | Mitotic kinesin inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080194653-A1 | Therapeutic Agent For Solid Tumor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-08-14 | — | — | US | disclosed |
| EP-1908755-A1 | THERAPEUTIC AGENT FOR RESTENOSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-04-09 | — | — | EP | disclosed |
| EP-1870404-A1 | AGENT FOR TREATMENT OF HEMATOPOIETIC TUMOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
| EP-1867640-A1 | AGENT FOR TREATMENT OF SOLID TUMOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-12-19 | — | — | EP | disclosed |
| EP-1847534-A2 | Thiadiazoline derivative | Kyowa Hakko Kogyo Co., Ltd (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070213380-A1 | Thiadiazoline derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070155804-A1 | Mitotic kinesin inhibitor | KYOWA HAKKO KOGYO CO., LTD. OF TOKYO, JAPAN FUJI PHOTO FILM CO., LTD. KANAGAWA, JAPAN | 2007-07-05 | — | — | US | disclosed |
| US-20060074113-A1 | Thiadiazoline derivative | KYOWA KIRIN CO., LTD. (JP) | 2006-04-06 | — | — | US | disclosed |
| EP-1616866-A1 | M-STAGE KINESIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
| EP-1454903-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074113-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | CA12 4720/4885CA1 4761/4885CA2 4175/4885 |
| US-20070155804-A1 | Mitotic kinesin inhibitor | KIF15, KIF5A, KIF5B | CA12 4520/4885CA1 4204/4885CA2 2863/4885 |
| US-20070213380-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | CA12 4720/4885CA1 4761/4885CA2 4175/4885 |
| US-20110004000-A1 | Mitotic Kinesin Inhibitor | KIF15, KIF5A, KIF5B | CA12 4520/4885CA1 4204/4885CA2 2863/4885 |
| US-20080194653-A1 | Therapeutic Agent For Solid Tumor | HRH3, TP53, VHL | CA12 1919/4885CA1 3403/4885CA2 2864/4885 |
| US-20110275827-A1 | Mitotic Kinesin Inhibitor | KIF15, KIF5A, KIF5B | CA12 4520/4885CA1 4204/4885CA2 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.